Could metformin modulate the outcome of chronic murine toxoplasmosis?

Autor: Gomaa MM; Department of Medical Parasitology, Faculty of Medicine, Alexandria University, Alexandria, Egypt., Nabil El Achy S; Department of Pathology, Faculty of Medicine, Alexandria University, Alexandria, Egypt., Hezema NN; Department of Medical Parasitology, Faculty of Medicine, Alexandria University, Alexandria, Egypt. Electronic address: nehalnassef@gmail.com.
Jazyk: angličtina
Zdroj: Acta tropica [Acta Trop] 2024 Oct; Vol. 258, pp. 107339. Date of Electronic Publication: 2024 Jul 29.
DOI: 10.1016/j.actatropica.2024.107339
Abstrakt: Toxoplasmosis is a pervasive parasitic infection possessing a chief impact on both public health and veterinary medicine. Unfortunately, the commercially-available anti-Toxoplasma agents have either serious side effects or diminished efficiency, specifically on the Toxoplasma tissue cysts. In the present study, metformin (The first-line treatment for type 2 diabetes mellitus) was investigated for the first time against chronic cerebral toxoplasmosis in mice model experimentally-infected with ME49 strain versus spiramycin. Two metformin regimens were applied; starting one week before the infection and four weeks PI. Parasitological, ultrastructural, histopathological, immunohistochemical, immunological, and biochemical assessments were performed. The anti-parasitic effect of metformin was granted by the statistically-significant reduction in tissue-cyst burden in both treatment regimens. This was accompanied by markedly-mutilated ultrastructure and profound amelioration of the cerebral histopathology with remarkable decline in the brain CD4 + and CD8 + T cell count. Besides, diminution of anti-Toxoplasma IgG and brain GSH levels was evident. Ultimately, the present findings highlighted the powerful promising therapeutic role of metformin in the management of chronic toxoplasmosis on a basis of anti-parasitic, anti-inflammatory, and anti-oxidant possessions.
Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: